Company intelligence / Profile preview
Huons Global
Seongnam-si, South Koreahuonsglobal.com ↗
- Ownership
- Private
- Employees
- ~2100
- Development stage
- Phase 3
01
Overview
Huons Global has a diverse portfolio of over 300 specialty pharmaceuticals including eye drops, injectables, wellness drugs, and health supplements. Their botulinum toxin product Liztox/Hutox has received approvals in multiple countries including South Korea and Iraq.
- Therapeutic areas
- OtherDermatologyOphthalmologyEndocrinology
- Modalities
- Botulinum toxinHyaluronic acidPDRNBiopharmaceuticalsPeptidesEnzymeBiologics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
IMEIK (investment contract signed in June 2021)
Beyond the preview
Go deeper on Huons Global.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huons Global.